Richter BioLogics stands at the forefront of contract development and manufacturing (CDMO) sphere, with a specialized focus on products derived from bacteria and yeasts. Our two facilities boast capacities of 2 x 1,500L and 300L, facilitating the production of antibodies, including VHH/Nanobodies, proteins, vaccines and plasmid DNA. RB offers further proven capabilities in cell-free protein production (CFPS).

With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients globally and through every stage of production. We offer robust process- and cell line development, supply products for clinical trials, commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence and in time.

Services:

1. Strain and process development
2. In-house analytical services meeting EMA, FDA, and global standards.
3. Technology transfers
4. Clinical trial support
5. Performance of PPQ
6. Commercial market supply
7. Capacities of 2 x 1,500L and 300L